近7亿美元,再揽MNC大单,中国的BD“顶流”又出手了

医药魔方
23 Jun

—各奖项申报陆续启动,欢迎关注—在2025年的国产创新药出海热潮里,一家多次与制药巨头“联姻”的Biotech,再度拿下了一笔重磅交易。6月23日,和铂医药与大冢制药达成全球战略合作,双方将共同推进用于治疗自身免疫性疾病的BCMAxCD3双特异性T细胞衔接器(TCE)的开发。据此,和铂医药将获得总计4700万美元的首付款和近期里程碑付款,此外还有权获得高达6.23亿美元的额外付款,以及基于未来产品...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10